Active Ingredient History

  • Now
Tridihexethyl is a synthetic anticholinergic agent which was marketed under the brand name Pathilon as an adjunct in the treatment of peptic ulcer disease. However, it is no longer available in the US market. Tridihexethyl may block all three types of muscarinic receptors including M-1 receptors in the CNS and ganglia, M-2 receptors in the heart, and M-3 receptors. The muscarinic acetylcholine receptors mediate various cellular responses including inhibition of adenylate cyclase, the breakdown of phosphoinositides, and modulation of potassium channels through the action of G proteins. Tridihexethyl inhibits vagally mediated reflexes by antagonizing the action of acetylcholine. This, in turn, reduces the secretion of gastric acids in the stomach. Tridihexethyl was also examined for effect on patients with acquired nystagmus where four out of six patients showed improvement, but due to the profile usage of Tridihexethyl to treat nystagmus was limited.   NCATS

More Chemistry
(3-cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium iodide | benzenepropanaminium, gamma-cyclohexyl-n,n,n-triethyl-gamma-hydroxy- | chloride of tridihexethyl | pathilon | tridihexethyl | tridihexethyl chloride | tridihexethyl decylsulfate | tridihexethyl iodide | tridihexylethyl chloride


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue